Aytu reports strong prescription growth for Natesto low-T drug

Tuesday September 26, 2017 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Natesto

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTUD), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that – through August -- Natesto prescriptions and factory sales have reached their highest levels to date, with a significant increase in the number of physicians prescribing Natesto.Aytu_logoUSE

Natesto is the company’s drug for treatment of low testosterone.

Aytu reported the following prescription and prescriber growth for August 2017 as part of its nationwide product launch:

  • Natesto total prescriptions for the month of August were 753, representing a 25% increase over July total prescriptions and a 178% increase over March 2017.
  • The number of prescribers of Natesto for the month of August was 351, an 18% increase over July and a 78% increase over March 2017.

Additionally, factory sales for August were $518,000, the company said, corresponding to a growth rate of approximately 25% over July.

With this continued growth rate, Aytu said it remains positioned to achieve cash flow breakeven in the next four to five quarters. 

"We continue to be very encouraged by the Natesto prescription trends and the increasing number of men that are being helped from the benefits of Natesto for the treatment of their hypogonadism,” said Josh Disbrow, Aytu’s CEO.

“In August, we recorded the company's highest single month in terms of factory sales revenue, which was anticipated based on the monthly prescription trends. 

“These trends are in-line with our internal projections, and we believe Natesto's strong prescription growth will continue."